News · 26 weeks68+50%
2026-04-192026-10-11
Mix3090d
- Other13(43%)
- Insider9(30%)
- SEC Filings3(10%)
- Leadership3(10%)
- Analyst1(3%)
- Dividends1(3%)
Latest news
25 items- PRBD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026FRANKLIN LAKES, N.J., Oct. 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, November 5, 2026 to discuss the Company's financial results for its fourth quarter and full year of fiscal 2026, which ended on September 30, 2026, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materia
- PRBD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures WorldwidePhysicians, policymakers, and global health experts urge broader access to monitoring technologies that can help identify life-threatening complications earlier, helping more mothers survive childbirth and giving babies a healthier start in life.FRANKLIN LAKES, N.J., Oct. 8, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, the Global Surgery Foundation (GSF) and the Business Council for International Understanding (BCIU) brought together healthcare, government, academia, and industry leaders to advance solutions aimed at reducing maternal mortality worldwide. On the sidelines of the 81st United Nations General Assembly (UNGA), p
- PRBD Strengthens Leadership in Peripheral Vascular Innovation with Positive AGILITY Trial ResultsData through 9 months of follow-up from this ongoing 36-month study demonstrate high vessel patency, low reintervention rates and meaningful improvements in mobility and symptoms, providing evidence supporting the treatment of complex iliac artery disease.FRANKLIN LAKES, N.J., Oct. 7, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced positive nine-month results from the iliac cohort of the AGILITY Investigational Device Exemption trial evaluating the Revello™ Vascular Covered Stent. Presented at VIVA 2026 by Sean Lyden, M.D., global lead principal investigator for AGILITY, the results demonstrated strong safety an
- PRBD Celebrates 65 Years of Manufacturing, Innovation and Community Partnership in CanaanGenerations of Connecticut employees have helped ensure the reliable supply of the BD® Syringe, an essential medical device clinicians rely on every day in patient care around the worldCANAAN, Conn., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today marked 65 years of manufacturing in Canaan, Conn., the birthplace of the world's first fully sterile, single-use disposable plastic syringe and the largest syringe manufacturing operation in the United States.The site opened in 1961 with eight employees in a 25,000-square-foot building producing about 10 million syringes a year. The invention of the BD® Syringe helped en
- PRBD Appoints Ferass Abuzaina as Worldwide President of SurgeryFRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Ferass Abuzaina has been named worldwide president of the Surgery business unit at BD, effective immediately.Abuzaina will be responsible for driving the global strategic, operational, and commercial performance of Surgery. He will be based out of BD Surgery's headquarters in Warwick, RI, and will report to Peter Menziuso, executive vice president and president of the Interventional segment."Surgery is well-positioned for its next chapter of growth, and Ferass is the right leader to help us build on that momentum," said Menziuso.
- PRBD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare ResilienceAgreement supports significant investments in U.S. manufacturing, strengthens healthcare resilience and increases domestic production of essential medical consumables used in approximately 90% of U.S. hospital visits FRANKLIN LAKES, N.J., Oct. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), one of the world's leading medical technology companies and the nation's largest manufacturer of essential medical consumables, today announced a landmark partnership with the U.S. Government to expand domestic manufacturing and strengthen the resilience of supply chains for essential medical consumables relied on by clinicians and patients every day. Recognizing BD's critical ro
- INSIDEREVP, Chief Revenue Officer Feld Michael sold $13,961 worth of shares (76 units at $183.70) as part of a pre-agreed trading plan, decreasing direct ownership by 0.39% to 19,644 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- PRBD Celebrates 70 Years of Manufacturing, Innovation and Community Partnership in SandyGenerations of Utah employees have helped ensure the reliable supply of essential medical devices that clinicians use every day to care for patients around the worldSANDY, Utah, Sept. 29, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today marked 70 years of manufacturing in Sandy, Utah, a key part of the company's U.S. manufacturing network and a critical source of the medical technologies healthcare providers and patients depend on for daily care worldwide. Founded in 1956 as Deseret Pharmaceuticals, the Sandy site has played a significant role in the evolutio
- PRArthur Hu to Join BD as Chief Information and Digital OfficerFRANKLIN LAKES, N.J., Sept. 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Arthur (Art) Hu has been named executive vice president and chief information and digital officer, effective September 30. Hu brings more than 25 years of experience leading global technology, digital and business transformation initiatives at scale. He joins BD from Lenovo Group, where he most recently served as senior vice president, global chief information officer and chief technology and delivery officer for the Solutions and Services Group. There, his respons
- PRBD Advances Intelligent Robotics to Transform the Future of Pharmacy Care at FairviewFirst-of-its-kind U.S. deployment of BD Vmax 160 expands pharmacy automation beyond traditional dispensing, helping health systems manage growing demand for specialty therapies, refrigerated medications, and increasingly complex fulfilment needsFRANKLIN LAKES, N.J., Sept. 14, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Fairview Health Services has become the first health system in the United States to deploy the BD Vmax 160, a next generation pharmacy automation robot designed to help health systems manage the increasing complexity of specialty therapies and refrigerated medicines in high-volume, centra
- INSIDEREVP & Chief Financial Officer Roque Vitor covered exercise/tax liability with 190 shares, decreasing direct ownership by 2% to 8,041 units (SEC Form 4) (withholding tax)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDEREVP, Chief Revenue Officer Feld Michael sold $31,101 worth of shares (165 units at $188.49) as part of a pre-agreed trading plan, decreasing direct ownership by 0.83% to 19,720 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- PRBD Extends Leadership in Advanced Tissue Regeneration Through Continued Clinical InnovationSTANCE trial surpasses a key enrollment milestone, advancing the clinical evaluation of GalaFLEX LITE™ Scaffold and generating evidence to support its use in breast revision surgery for capsular contractureFRANKLIN LAKES, N.J., Aug. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with the STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture. The study has reached its first enrollment milestone, with 274 patients treated across 33 active U.S. sites, triggering the
- PRBD to Present at Wells Fargo 21st Annual Healthcare ConferenceFRANKLIN LAKES, N.J., Aug. 26, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 9:30 a.m. Eastern Time. The live webcast of BD's presentation can be accessed from the BD investor relations website, investors.bd.com. A replay of the event will be available on the same webpage following its conclusion.About BDBD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma syste
- INSIDEREVP, Chief Revenue Officer Feld Michael covered exercise/tax liability with 1,049 shares, decreasing direct ownership by 5% to 19,885 units (SEC Form 4) (for withholding tax)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- PRBD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to RetireFRANKLIN LAKES, N.J., Aug. 17, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8. Sorsher brings more than 30 years of experience leading quality organizations across world-class MedTech companies. Most recently, he served as chief quality officer at Edwards Lifesciences, where he led advancing quality excellence while supporting innovation, growth and operational performance across a complex global business. Throughout his career, Sorsher has b
- INSIDERChairman, CEO and President Polen Thomas E Jr exercised 43,278 shares at a strike of $167.25, returned $7,238,310 worth of shares to the company (39,126 units at $185.00) and sold $768,120 worth of shares (4,152 units at $185.00) as part of a pre-agreed trading plan (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDEREVP and President, EMEA Goette Roland sold $440,888 worth of shares (2,438 units at $180.84), decreasing direct ownership by 14% to 14,856 units (SEC Form 4)4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- PRBD Accelerates Advanced Tissue Regeneration Strategy with Landmark PREVENT TrialEnrollment completed in the first large-scale randomized study evaluating Phasix™ Mesh for incisional hernia prevention, a significant unmet need following abdominal surgeryFRANKLIN LAKES, N.J., Aug. 12, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced a significant milestone in its advanced tissue regeneration strategy and expansion efforts with successful completion of enrollment in the PREVENT clinical trial evaluating Phasix™ Mesh for the prevention of incisional hernias. The study enrolled 477 patients across 32 sites in the United States and E
- INSIDERSEC Form 4 filed by Director Huffines Robert Luther4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- INSIDERSEC Form 4 filed by Director Byington Carrie L4 - BECTON DICKINSON & CO (0000010795) (Issuer)
- SECSEC Form 10-Q filed by Becton Dickinson and Company10-Q - BECTON DICKINSON & CO (0000010795) (Filer)
- SECBecton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BECTON DICKINSON & CO (0000010795) (Filer)
- PRBD Reports Third Quarter Fiscal 2026 Financial ResultsRevenue of $5.0 billion increased 5.4% as reported, 4.4% FXNGAAP and adjusted diluted EPS from continuing operations of $1.64 and $3.23, respectivelyYear-to-date cash from continuing operations increased 33.3% to $2.1 billion and free cash flow increased 44.6% to $1.7 billionCompany updates full-year guidance to reflect ongoing momentum, expects revenue growth toward the high end of its range and raises midpoint of adjusted diluted EPS guidanceFRANKLIN LAKES, N.J., Aug. 6, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2026 third quarter, which ended June 30, 2026. "We delivered a strong
- PREMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launchCollaboration pairs leadership in pharmaceuticals and advanced drug delivery technology to support a consistent, reliable treatment experience for metabolic disease patients.FRANKLIN LAKES, N.J. and SÃO PAULO, July 29, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, today announced their collaboration in the launch of a semaglutide therapy in Brazil. This collaboration and launch underscore a shared commitment to addressing patients' ongoing healthcare challenges associated with chronic diseases, including obesity and type 2 diabetes.
BDX FAQ
7 questionsWhat does Becton Dickinson and Company do?
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids...Where does BDX stock trade?
Becton Dickinson and Company (BDX) is listed on NYSE.What sector and industry is BDX in?
Becton Dickinson and Company operates in the Health Care sector, Medical/Dental Instruments industry.Does BDX pay a dividend?
BDX's most recent ex-dividend date was 2026-09-09 with a cash dividend of $1.05 per share. No future ex-date is on file yet.What are analysts saying about BDX?
Becton Dickinson and Company has had 8 recent analyst actions on file. The most recent action was from UBS: Buy with a $1900.00 price target on 2026-07-28. Recent price targets cluster around $1900.00.What companies are similar to BDX?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), ABT (Abbott Laboratories), MDT (Medtronic plc.), MCK (McKesson Corporation), SYK (Stryker Corporation). Compare BDX side-by-side with any of them on Quantisnow.How can I track BDX on Quantisnow?
Quantisnow aggregates Becton Dickinson and Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BDX to receive live email and push alerts on every new disclosure.